Plasma interferon-γ-inducible protein 10 (IP-10) levels correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis

Suárez, Isabelle; Rohr, Samuel; Stecher, Melanie; Lehmann, Clara; Winter, Sandra; Jung, Norma; Berger, M.; Wyen, Christoph; Malin, Jakob J; Fischer, Julia; Horn, Carola; Neuhann, Florian; Püsken, Michael; Plum, Georg; Fätkenheuer, Gerd; Rybniker, Jan

doi:10.1007/s15010-020-01541-1

Cited by 7 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, immunohistochemical analyses have demonstrated overexpression of MIG, IP-10, and I-TAC especially in granulomas in 26 patients with tubal TB, and their expression levels are correlated with disease severity [37]. Another study reported that unstimulated blood levels of IP-10 are correlated with paradoxical reaction in TB-LAP [38]. TB antigen ESAT6-induced MIG release is increased in TB-LAP and correlated with severity of disease [39].…”

Section: Discussionmentioning

confidence: 99%

TB Antigen-Stimulated CXCR3 Ligand Assay for Diagnosis of Tuberculous Lymphadenitis

Chung

Lee

Park

et al. 2021

IJERPH

View full text Add to dashboard Cite

The diagnosis of tuberculous lymphadenitis (TB-LAP) is challenging. We evaluated the role of blood CXC chemokine receptor 3 (CXCR3) ligands in its diagnosis. A total of 65 lymphadenopathy patients were enrolled and lymph node sampling was performed. We also recruited 113 control subjects, consisting of 27 with positive results and 86 with negative results, in the interferon (IFN)-γ release assay (IGRA). In all study subjects, whole-blood samples were collected using the IGRA methodology. After incubation, plasma levels of IFN-γ and two CXCR3 ligands, IFN-inducible T-cell a chemoattractant (I-TAC) and monokine induced by IFN-γ (MIG), were measured using immunoassay. Fifty-three TB-LAP patients were enrolled. TB antigen-stimulated IFN-γ, I-TAC, and MIG levels were all significantly higher in the TB-LAP patients than in the controls and non-TB-LAP patients. The levels of I-TAC and MIG, but not IFN-γ, showed significant differences between the TB-LAP patients and IGRA-positive controls. Area under the receiver operating characteristic curves (AUROCs) of IFN-γ, I-TAC, and MIG were 0.955, 0.958, and 0.959, respectively, for differentiating TB-LAP from control group, and were 0.912, 0.956, and 0.936, respectively, for differentiating TB-LAP from non-TB-LAP. In conclusion, the TB antigen-stimulated MIG and I-TAC could be useful biomarkers in the diagnosis of TB-LAP.

show abstract

Section: Discussionmentioning

confidence: 99%

TB Antigen-Stimulated CXCR3 Ligand Assay for Diagnosis of Tuberculous Lymphadenitis

Chung

Lee

Park

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…The increasing trend in discontinuations due to regimen simplification and/or convenience or provider-initiated discontinuations during the later period also suggests a better tolerability profile and dosing convenience of newer regimens. Several studies showed a better durability of once-daily, especially STR [ 11 , 18 ]. Although INSTI-based regimens showed less discontinuation compared to other classes, we could not find any difference between single or multi-tablet once daily regimens in the class.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, our results are mostly valid for the time period studied in our country and may not be applicable to other countries. Recent studies from Germany reported that most changes within the first year were not driven by virologic failure or adverse events, but were strategic such as preventing future toxicities with increasing options of modern ART [ 11 , 12 ]. We noted that strategic treatment changes also increased in Turkey despite being a middle-income country in the late period of the study with the unrestricted availability of new drugs.…”

Section: Discussionmentioning

confidence: 99%

Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011–2017

Korten

Gökengin

Eren³

et al. 2021

AIDS Res Ther

View full text Add to dashboard Cite

Background There is limited evidence on the modification or stopping of antiretroviral therapy (ART) regimens, including novel antiretroviral drugs. The aim of this study was to evaluate the discontinuation of first ART before and after the availability of better tolerated and less complex regimens by comparing the frequency, reasons and associations with patient characteristics. Methods A total of 3019 ART-naive patients registered in the HIV-TR cohort who started ART between Jan 2011 and Feb 2017 were studied. Only the first modification within the first year of treatment for each patient was included in the analyses. Reasons were classified as listed in the coded form in the web-based database. Cumulative incidences were analysed using competing risk function and factors associated with discontinuation of the ART regimen were examined using Cox proportional hazards models and Fine-Gray competing risk regression models. Results The initial ART regimen was discontinued in 351 out of 3019 eligible patients (11.6%) within the first year. The main reason for discontinuation was intolerance/toxicity (45.0%), followed by treatment simplification (9.7%), patient willingness (7.4%), poor compliance (7.1%), prevention of future toxicities (6.0%), virologic failure (5.4%), and provider preference (5.4%). Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based (aHR = 4.4, [95% CI 3.0–6.4]; p < 0.0001) or protease inhibitor (PI)-based regimens (aHR = 4.3, [95% CI 3.1–6.0]; p < 0.0001) relative to integrase strand transfer inhibitor (InSTI)-based regimens were significantly associated with ART discontinuation. ART initiated at a later period (2015-Feb 2017) (aHR = 0.6, [95% CI 0.4–0.9]; p < 0.0001) was less likely to be discontinued. A lower rate of treatment discontinuation for intolerance/toxicity was observed with InSTI-based regimens (2.0%) than with NNRTI- (6.6%) and PI-based regimens (7.5%) (p < 0.001). The percentage of patients who achieved HIV RNA < 200 copies/mL within 12 months of ART initiation was 91% in the ART discontinued group vs. 94% in the continued group (p > 0.05). Conclusion ART discontinuation due to intolerance/toxicity and virologic failure decreased over time. InSTI-based regimens were less likely to be discontinued than PI- and NNRTI-based ART.

show abstract

“…IP-10 has comparable accuracy to IGRAs in identifying Mtb. infection in adults and children and may even perform better in HIV-infected individuals and the young [11,[13][14][15][16][17][18][19][20]. Additionally, IP-10 has been suggested as a potential biomarker for treatment monitoring, but studies in pediatric populations are scarce [21,22].…”

Section: Introductionmentioning

confidence: 99%

IP-10 for the Diagnosis and Treatment Monitoring of Tuberculosis in Children

Strzelak,

Komorowska-Piotrowska,

Borowa

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Purpose: To determine the utility of interferon-gamma-inducible protein 10 (IP-10) for identifying active tuberculosis (TB) and TB infection (TBI) in children in BCG-vaccinated populations, establish its diagnostic performance characteristics, and evaluate changes in IP-10 level during anti-TB chemotherapy. Methods: Concentrations of IP-10 and IFN-γ were measured in QuantiFERON-TB Gold (QFT) supernatants in children with suspected TB or due to recent TB contact. A total of 225 children were investigated: 33 with active TB, 48 with TBI, 83 TB contacts, 20 with suspected TB but other final diagnoses, and 41 controls. In 60 children, cytokine responses were evaluated at a follow-up visit after 2 months of anti-TB treatment. Results: IP-10 expression was significantly higher in infected children (active TB and TBI cases) than in uninfected individuals. IP-10 proved effective in identifying TB infection at its optimal cut-off (>1084.5 pg/mL) but was incapable of differentiating between children with active TB and TBI. Combining IP-10 and IFN-γ increased the QFT sensitivity. IP-10 but not IFN-γ decreased significantly during anti-TB treatment in children with active TB (p = 0.003). Conclusion: IP-10 identifies TB infection and declines during anti-TB chemotherapy in children. Incorporating IP-10 into new immunodiagnostic assays could improve TB diagnosis and allow for treatment monitoring.

show abstract

Plasma interferon-γ-inducible protein 10 (IP-10) levels correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis

Cited by 7 publications

References 36 publications

TB Antigen-Stimulated CXCR3 Ligand Assay for Diagnosis of Tuberculous Lymphadenitis

TB Antigen-Stimulated CXCR3 Ligand Assay for Diagnosis of Tuberculous Lymphadenitis

Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011–2017

IP-10 for the Diagnosis and Treatment Monitoring of Tuberculosis in Children

Contact Info

Product

Resources

About